天美传媒

Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.




 

Dr. Marron received his medical degree from the David Geffen School of Medicine at UCLA in 2008. He completed his residency in Pediatrics at Stanford University and his fellowship in Clinical Medical Ethics at the University of Chicago followed by his fellowship in Pediatric Hematology/Oncology at Boston Children's Hospital and the Dana-Farber Cancer Institute. Dr. Marron also received an MPH in 2016 from the Harvard T.H. Chan School of Public Health. Jonathan cares for pediatric oncology patients in the inpatient setting at Boston Children's Hospital and in the outpatient clinic at the Dana-Farber Cancer Institute. His research interests are in ethics and decision-making, health services, clinical genomics, informed consent, and medical uncertainty. Much of Dr. Marron's current work focuses on patient, parent and physician decision-making regarding pediatric precision cancer medicine. He also teaches medical ethics to medical students and graduate students through his role as teaching faculty at the Harvard Medical School Center for Bioethics.

Dr. Gillani uses computational techniques to understand the markers in cancer and normal patient genomes that are associated with the development and progression of disease, leveraging these insights to inform novel approaches to the treatment of pediatric cancer. He cares for patients with a range of solid tumor and hematologic malignancy diagnoses, with the overall aim of translating research insights to improved patient management.